Targacept (TRGT +0.2%) completes enrollment in a Phase 2a study of its schizophrenia treatment...

|By:, SA News Editor

Targacept (TRGT +0.2%) completes enrollment in a Phase 2a study of its schizophrenia treatment TC-5619 which treats the negative symptoms and cognitive dysfunction of the disease, something TRGT's CEO says is novel among treatment options.